Jazz Pharmaceuticals plc
JAZZ
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
8% upsideUndervalued by 8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.84 Billion |
|---|---|
| Enterprise Value | $18.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.84 |
| Beta | 0.27 |
| Outstanding Shares | 61,900,000 |
Return
| Return on Equity | 0.65% |
|---|---|
| Return on Assets | 0.25% |
| Return on Invested Capital | -1.50% |
Valuation & Multiples
| P/E Ratio | 496.35 |
|---|---|
| PEG | -119.11 |
| Price to Sales | 3.25 |
| Price to Book Ratio | 3.16 |
| Enterprise Value to Revenue | 4.17 |
| Enterprise Value to EBIT | -128.15 |
| Enterprise Value to Net Income | 627 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 1.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9766▲ 57.11% |
|---|---|
| Total Calls | 249,200▼ 64.71% |
| Total Puts | 243,368▼ 15.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.63%▲ 4.97% |
|---|---|
| Total Invested | $12.28B▲ 17.17% |
| Investors Holding | 585▼ 10.00% |
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...
Relevant Senate Committees
Provides critical analysis and scoring for tax legislation, which directly impacts corporate tax structures, capital investment, and overall profitability for all companies, including Jazz Pharmaceuticals, which operates across international borders.
Controls critical aspects like taxation (affecting a company like Jazz Pharmaceuticals, which is based in Ireland but operates heavily in the U.S.), trade, and entitlement spending (e.g., Medicare/Medicaid drug pricing), all of which directly impact pharmaceutical company profitability and market access.
Directly allocates federal funding for health agencies like the FDA and NIH, which are crucial for drug approval, research, and development, thereby directly impacting the operating environment and potential market for Jazz Pharmaceuticals.
This committee has direct oversight over the FDA (which approves Jazz's drugs like Xyrem and Sunosi) and the NIH (which funds biomedical research). Its decisions on drug approval processes, research funding, and labor policies directly impact pharmaceutical companies.
Has direct oversight over intellectual property (patents), which are fundamental to a biopharmaceutical company's value. Also regulates antitrust, and the DOJ (under its purview) investigates illegal marketing practices, a past issue for Jazz Pharmaceuticals.